Literature DB >> 24917137

RNA expression analysis of passive transfer myasthenia supports extraocular muscle as a unique immunological environment.

Yuefang Zhou1, Henry J Kaminski2, Bendi Gong3, Georgiana Cheng4, Jason M Feuerman5, Linda Kusner2.   

Abstract

PURPOSE: Myasthenia gravis demonstrates a distinct predilection for involvement of the extraocular muscles (EOM), and we have hypothesized that this may be due to a unique immunological environment. To assess this hypothesis, we took an unbiased approach to analyze RNA expression profiles in EOM, diaphragm, and extensor digitorum longus (EDL) in rats with experimentally acquired myasthenia gravis (EAMG).
METHODS: Experimentally acquired myasthenia gravis was induced in rats by intraperitoneal injection of antibody directed against the acetylcholine receptor (AChR), whereas control rats received antibody known to bind the AChR but not induce disease. After 48 hours, animals were killed and muscles analyzed by RNA expression profiling. Profiling results were validated using qPCR and immunohistochemical analysis.
RESULTS: Sixty-two genes common among all muscle groups were increased in expression. These fell into four major categories: 12.8% stress response, 10.5% immune response, 10.5% metabolism, and 9.0% transcription factors. EOM expressed 212 genes at higher levels, not shared by the other two muscles, and a preponderance of EOM gene changes fell into the immune response category. EOM had the most uniquely reduced genes (126) compared with diaphragm (26) and EDL (50). Only 18 downregulated genes were shared by the three muscles. Histological evaluation and disease load index (sum of fold changes for all genes) demonstrated that EOM had the greatest degree of pathology.
CONCLUSIONS: Our studies demonstrated that consistent with human myasthenia gravis, EOM demonstrates a distinct RNA expression signature from EDL and diaphragm, which is based on differences in the degree of muscle injury and inflammatory response. Copyright 2014 The Association for Research in Vision and Ophthalmology, Inc.

Entities:  

Keywords:  acetylcholine receptor; autoimmunity; complement; myasthenia gravis; skeletal muscle

Mesh:

Substances:

Year:  2014        PMID: 24917137      PMCID: PMC4102389          DOI: 10.1167/iovs.14-14422

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  71 in total

1.  Transcriptional profile of rat extraocular muscle by serial analysis of gene expression.

Authors:  Georgiana Cheng; John D Porter
Journal:  Invest Ophthalmol Vis Sci       Date:  2002-04       Impact factor: 4.799

2.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

3.  Novel modulation of neuronal nicotinic acetylcholine receptors by association with the endogenous prototoxin lynx1.

Authors:  Inés Ibañez-Tallon; Julie M Miwa; Hai Long Wang; Niels C Adams; Gregg W Crabtree; Steven M Sine; Nathaniel Heintz
Journal:  Neuron       Date:  2002-03-14       Impact factor: 17.173

4.  Expression profiling reveals metabolic and structural components of extraocular muscles.

Authors:  M Dominik Fischer; J Rafael Gorospe; Edward Felder; Sasha Bogdanovich; F Pedrosa-Domellöf; Rexford S Ahima; Neal A Rubinstein; Eric P Hoffman; Tejvir S Khurana
Journal:  Physiol Genomics       Date:  2002-03-05       Impact factor: 3.107

5.  The muscle ankyrin repeat proteins: CARP, ankrd2/Arpp and DARP as a family of titin filament-based stress response molecules.

Authors:  Melanie K Miller; Marie-Louise Bang; Christian C Witt; Dietmar Labeit; Charles Trombitas; Kaori Watanabe; Henk Granzier; Abigail S McElhinny; Carol C Gregorio; Siegfried Labeit
Journal:  J Mol Biol       Date:  2003-11-07       Impact factor: 5.469

6.  Markedly enhanced susceptibility to experimental autoimmune myasthenia gravis in the absence of decay-accelerating factor protection.

Authors:  Feng Lin; Henry J Kaminski; Bianca M Conti-Fine; Wei Wang; Chelliah Richmonds; M Edward Medof
Journal:  J Clin Invest       Date:  2002-11       Impact factor: 14.808

7.  Activated satellite cells in extraocular muscles of normal adult monkeys and humans.

Authors:  Linda K McLoon; Jonathan Wirtschafter
Journal:  Invest Ophthalmol Vis Sci       Date:  2003-05       Impact factor: 4.799

8.  Temporal gene expression profiling of dystrophin-deficient (mdx) mouse diaphragm identifies conserved and muscle group-specific mechanisms in the pathogenesis of muscular dystrophy.

Authors:  John D Porter; Anita P Merriam; Patrick Leahy; Bendi Gong; Jason Feuerman; Georgiana Cheng; Sangeeta Khanna
Journal:  Hum Mol Genet       Date:  2003-12-17       Impact factor: 6.150

9.  Susceptibility of ocular tissues to autoimmune diseases.

Authors:  Henry J Kaminski; Zhuyi Li; Chelliah Richmonds; Robert L Ruff; Linda Kusner
Journal:  Ann N Y Acad Sci       Date:  2003-09       Impact factor: 5.691

10.  Dissection of temporal gene expression signatures of affected and spared muscle groups in dystrophin-deficient (mdx) mice.

Authors:  John D Porter; Anita P Merriam; Patrick Leahy; Bendi Gong; Sangeeta Khanna
Journal:  Hum Mol Genet       Date:  2003-08-01       Impact factor: 6.150

View more
  9 in total

1.  Guidelines for pre-clinical assessment of the acetylcholine receptor--specific passive transfer myasthenia gravis model-Recommendations for methods and experimental designs.

Authors:  Linda L Kusner; Mario Losen; Angela Vincent; Jon Lindstrom; Socrates Tzartos; Konstantinos Lazaridis; Pilar Martinez-Martinez
Journal:  Exp Neurol       Date:  2015-03-03       Impact factor: 5.330

2.  Mitochondrial bioenergetics in ocular fibroblasts of two myasthenia gravis cases.

Authors:  Tarin A Europa; Melissa Nel; Maribanyana R Lebeko; Jeannine M Heckmann
Journal:  IBRO Neurosci Rep       Date:  2022-04-21

3.  The African-387 C>T TGFB1 variant is functional and associates with the ophthalmoplegic complication in juvenile myasthenia gravis.

Authors:  Melissa Nel; Joy-Mari Buys; Robyn Rautenbach; Shaheen Mowla; Sharon Prince; Jeannine M Heckmann
Journal:  J Hum Genet       Date:  2015-12-03       Impact factor: 3.172

4.  Differential RNA Expression Profile of Skeletal Muscle Induced by Experimental Autoimmune Myasthenia Gravis in Rats.

Authors:  Henry J Kaminski; Keiichi Himuro; Jumana Alshaikh; Bendi Gong; Georgiana Cheng; Linda L Kusner
Journal:  Front Physiol       Date:  2016-11-10       Impact factor: 4.566

5.  The Role of Osteopontin and Its Gene on Glucocorticoid Response in Myasthenia Gravis.

Authors:  Yanchen Xie; Hai-Feng Li; Liang Sun; Linda L Kusner; Shuhui Wang; Yunxiao Meng; Xu Zhang; Yu Hong; Xiang Gao; Yao Li; Henry J Kaminski
Journal:  Front Neurol       Date:  2017-05-31       Impact factor: 4.003

6.  Investigational RNAi Therapeutic Targeting C5 Is Efficacious in Pre-clinical Models of Myasthenia Gravis.

Authors:  Linda L Kusner; Kristina Yucius; Manjistha Sengupta; Andrew G Sprague; Dhruv Desai; Tuyen Nguyen; Klaus Charisse; Satya Kuchimanchi; Rajeev Kallanthottathil; Kevin Fitzgerald; Henry J Kaminski; Anna Borodovsky
Journal:  Mol Ther Methods Clin Dev       Date:  2019-05-10       Impact factor: 6.698

7.  Profiling of patient-specific myocytes identifies altered gene expression in the ophthalmoplegic subphenotype of myasthenia gravis.

Authors:  Melissa Nel; Sharon Prince; Jeannine M Heckmann
Journal:  Orphanet J Rare Dis       Date:  2019-01-29       Impact factor: 4.123

Review 8.  The Muscle Is Not a Passive Target in Myasthenia Gravis.

Authors:  Jean-Thomas Vilquin; Alexandra Clarissa Bayer; Rozen Le Panse; Sonia Berrih-Aknin
Journal:  Front Neurol       Date:  2019-12-19       Impact factor: 4.003

9.  Gene expression profiling of orbital muscles in treatment-resistant ophthalmoplegic myasthenia gravis.

Authors:  Tarin A Europa; Melissa Nel; Jeannine M Heckmann
Journal:  Orphanet J Rare Dis       Date:  2020-12-11       Impact factor: 4.123

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.